共 49 条
- [21] Rituximab (Mabthera®) as single agent and in combination with interferon-α-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas.: Preliminary results of a randomized phase II study (M39035).BLOOD, 1999, 94 (10) : 263B - 263BKimby, EGeisler, CHagberg, HHolte, HLehtinen, TSundström, CSamuelsson, J
- [22] Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (20) : 2279 - U92Bielack, Stefan S.Smeland, SigbjornWhelan, Jeremy S.Marina, NeyssaJovic, GordanaHook, Jane M.Krailo, Mark D.Gebhardt, MarkPapai, ZsuzsannaMeyer, JamesNadel, HelenRandall, R. LorDeffenbaugh, ClaudiaNagarajan, RajaramBrennan, BernadetteLetson, G. DouglasTeot, Lisa A.Goorin, AllenBaumhoer, DanielKager, LeoWerner, MathiasLau, Ching C.Hall, Kirsten SundbyGelderblom, HansMeyers, PaulGorlick, RichardWindhager, ReinhardHelmke, KnutEriksson, MikaelHoogerbrugge, Peter M.Schomberg, PaulaTunn, Per-UlfKuehne, ThomasJuergens, Heribertvan den Berg, HenkBohling, TomPicton, SusanRenard, MarleenReichardt, PeterGerss, JoachimButterfass-Bahloul, TrudeMorris, CarolHogendoorn, Pancras C. W.Seddon, BeatriceCalaminus, GabrieleMichelagnoli, MariaDhooge, CatharinaSydes, Matthew R.Bernstein, Mark
- [23] A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Brancato, Sam JosephStamatakis, LambrosApolo, Andrea BorgheseFowler, SarahSchlom, JeffreyGulley, James L.Agarwal, Plyush K.
- [24] MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response" randomization.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)Bielack, Stefan S.Smeland, SigbjornWhelan, JeremyMarina, NeyssaHook, JaneJovic, GordanaKrailo, Mark D.Butterfass-Bahloul, TrudeKuehne, ThomasEriksson, MikaelTeot, Lisa A.Gelderblom, HansKager, LeoHall, Kirsten SundbyGorlick, Richard GregRandall, R. LorHogendoorn, Pancras C. W.Calaminus, GabrieleSydes, Matthew RobertBernstein, Mark L.
- [25] Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma GroupBLOOD, 2012, 120 (21)Kimby, EvaOstenstad, BjornBrown, Peter de NullyHolte, Harald, Jr.Hagberg, HansErlanson, MartinLinden, OlaNordstrom, MarieSundstrom, Christer
- [26] UPDATED RESULTS FROM A RANDOMIZED PHASE 2 DOSE-RANGING STUDY OF THE JAK2-SELECTIVE INHIBITOR SAR302503 IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS (MF)HAEMATOLOGICA, 2013, 98 : 458 - 458Talpaz, M.Jamieson, C.Gabrail, N.Lebedinsky, C.Gao, G.Patki, A.Lui, F.Tefferi, A.Pardanani, A.
- [27] CLINICAL OUTCOMES OF A RANDOMIZED, PROSPECTIVE, PHASE II STUDY TO DETERMINE THE EFFICACY OF BACILLUS CALMETTE-GUERIN (BCG) GIVEN IN COMBINATION WITH PANVAC VERSUS BCG GIVEN ALONE IN ADULTS WITH HIGH GRADE BCG-REFRACTORY NON-MUSCLE INVASIVE BLADDER CANCERJOURNAL OF UROLOGY, 2021, 206 : E302 - E302Saoud, RagheedTelfer, SiobhanMaruf, MahirSinger, EricWeiss, RobertJang, ThomasElsamra, SammyMarino, MariaValera, VladimirRodriguez, Beatriz WalterRailkar, ReemaDolan, RebeccaBellfield, SoniaStamatakis, LambrosShih, JoannaBrancato, SamDonohue, ReneePico Navarro, CesarApolo, AndreaGulley, JamesSchlom, JeffreyAgarwal, Piyush
- [28] BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 StudyBLOOD, 2023, 142Lavie, DavidRibrag, VincentLoschi, MichaelYannakou, Costas K.Alwan, MaanAbulafia, Adi SchachamHernandez-Rivas, Jesus MariaVolchek, YuliaFong, Chun YewBonifacio, MassimilianoKiladjian, Jean-JacquesIanotto, Jean-ChristopheGarcia Gutierrez, ValentinTucci, AlessandraXicoy, BlancaAl-Ali, Haifa KathrinTalpaz, MosheGerber, Jonathan M.Raman, InduTomuleasa, CiprianLee-Hoeflich, Si TuenDas, SharmilaWu, BinZhao, QianKim, EunheeEsposito, OrianaLiu, YuNikolova, ZarianaTehlirian, ChristopherCoker, ShodeindeAyala, Rosa
- [29] Efficacy and Safety Results From the NeoPembrOV Study, a Randomized Phase 2 Trial of Neoadjuvant Chemotherapy With or Without Pembrolizumab Followed by Interval Debulking Surgery and Standard Systemic Therapy ± Pembrolizumab for Advanced High-Grade Serous Carcinoma: a GINECO StudyCLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 19 - 20不详
- [30] TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancerANNALS OF ONCOLOGY, 2019, 30Awada, A. H.Cortes, J.Slater, S.Macpherson, I.Csoszi, T.Bertrand, J. -B.Clermont, A. -S.Pollard, R.Chrestia-Blanchine, R.Biswas-Baldwin, N.Youssoufian, H.El-Hariry, I.